Live price temporarily unavailable.
Avalo Therapeutics (AVTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.15M | $27.8M | $7.03M | $6.75M | $6.70M | $5.40M | $18.1M | $1.92M | $441.0K | $59.0K |
| Growth (year over year) | — | +2312.3% | −74.7% | −4.0% | −0.8% | −19.4% | +234.4% | −89.3% | −77.1% | −86.6% |
| Gross profit | $1.15M | $27.2M | $3.77M | — | $6.40M | $3.91M | $14.6M | $640.0K | — | — |
| Gross margin | 100.0% | 97.7% | 53.6% | — | 95.5% | 72.4% | 81.0% | 33.3% | — | — |
| Operating income | −$16.1M | $13.9M | −$35.4M | −$16.1M | −$72.8M | −$82.1M | −$37.4M | −$27.4M | −$68.5M | −$72.9M |
| Operating margin | −1394.6% | 49.9% | −503.4% | −239.1% | −1087.4% | −1521.6% | −207.4% | −1421.6% | −15535.6% | −123601.7% |
| Net income | −$16.5M | $11.9M | −$40.1M | −$16.1M | −$63.5M | −$84.4M | −$41.7M | −$31.5M | −$35.1M | −$78.3M |
| Net margin | −1428.6% | 42.7% | −569.9% | −238.1% | −947.9% | −1563.1% | −230.8% | −1639.5% | −7965.8% | −132642.4% |
| EPS (diluted) | −$1.87 | $0.42 | −$1.20 | — | — | — | −$1063.00 | −$113.58 | −$20.91 | −$5.84 |
| Balance sheet | ||||||||||
| Cash and equivalents | $5.13M | $2.47M | $10.6M | $3.61M | $18.9M | $54.6M | $13.2M | $7.42M | $134.5M | $15.9M |
| Total assets | $5.77M | $42.8M | $70.3M | $36.1M | $43.8M | $80.2M | $33.4M | $21.0M | $150.7M | $116.5M |
| Total liabilities | $5.56M | $14.9M | $49.3M | $15.1M | $19.2M | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Long-term debt | $0 | $0 | $14.3M | — | — | — | — | — | — | — |
| Shareholders' equity | $207.0K | $27.9M | $20.9M | $21.0M | $24.6M | $23.1M | −$10.9M | $7.30M | $133.0M | $83.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$14.6M | $12.6M | −$3.13M | −$19.1M | −$40.5M | −$70.9M | −$26.8M | −$30.7M | −$49.1M | −$51.5M |
| Capital expenditure | $34.9K | $23.3K | $564.4K | $262.0K | $63.0K | $113.0K | $95.0K | $158.0K | $0 | — |
| Free cash flow | −$14.6M | $12.6M | −$3.69M | −$19.4M | −$40.6M | −$71.0M | −$26.8M | −$30.8M | −$49.1M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $249.0K | $192.0K | — | — | $0 | $59.0K | — | — |
| Growth (year over year) | +5.5% | −66.3% | — | — | −100.0% | −69.3% | — | — |
| Operating income | −$12.9M | −$13.3M | −$14.7M | −$19.3M | −$19.2M | −$19.7M | −$20.9M | −$31.5M |
| Operating margin | −5165.1% | −6931.8% | — | — | — | −33461.0% | — | — |
| Net income | $23.0M | −$35.3M | −$13.1M | −$20.8M | −$30.6M | −$13.7M | −$19.6M | −$36.4M |
| Net margin | 9251.8% | −18405.7% | — | — | — | −23254.2% | — | — |
| EPS (diluted) | −$2.83 | $137.13 | −$1.25 | −$1.92 | −$2.19 | −$0.48 | −$0.98 | −$0.83 |
| Balance sheet | ||||||||
| Cash and equivalents | $81.9M | $134.5M | $125.0M | $42.3M | $27.0M | $15.9M | $25.0M | $85.4M |
| Total assets | $98.5M | $150.7M | $138.5M | $126.6M | $125.1M | $116.5M | $99.9M | $490.8M |
| Total liabilities | $75.7M | $17.7M | $15.9M | $22.0M | $33.6M | $33.4M | $31.6M | $42.1M |
| Shareholders' equity | $21.1M | $133.0M | $122.6M | $104.6M | $91.5M | $83.0M | $68.3M | $448.7M |
| Cash flow | ||||||||
| Operating cash flow | −$11.5M | −$15.0M | −$9.46M | −$11.4M | −$16.4M | −$14.2M | −$17.7M | −$20.0M |
| Capital expenditure | $0 | $0 | — | — | — | — | — | — |
| Free cash flow | −$11.5M | −$15.0M | — | — | — | — | — | — |
From Avalo Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Avalo Therapeutics in our feed yet.